MedTrace Logo

Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention

NCT04040946 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2023-08-01

No results posted yet for this study

Summary

The investigators hypothesize that positron emission tomography with fluorocholline (F18-choline PET) will reduce the proportion of unnecessary invasive surgery decisions and that the higher cost of positron emission tomography versus MIBI scintigraphy (Tc99m-sestaMIBI ) will be offset by lower cost in terms of type. surgery performed wisely and complications.

Conditions

  • Parathyroid Adenoma
  • Hyperparathyroidism
  • F18-choline

Interventions

DIAGNOSTIC_TEST

MIBI scintigraphy

Performing a MIBI scintigraphy, then, in the case of negativity, a single F18-choline PET

DIAGNOSTIC_TEST

F18-choline PET

Realization of a F18-choline PET, then, in case of negativity, a MIBI scintigraphy

Sponsors & Collaborators

  • Fondation de l'Avenir

    collaborator OTHER

  • Centre Francois Baclesse

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-19
Primary Completion
2022-05-05
Completion
2023-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04040946 on ClinicalTrials.gov